IL192507A0 - Use of alpha-hydroxy carbonyl compounds as reducing agents - Google Patents

Use of alpha-hydroxy carbonyl compounds as reducing agents

Info

Publication number
IL192507A0
IL192507A0 IL192507A IL19250708A IL192507A0 IL 192507 A0 IL192507 A0 IL 192507A0 IL 192507 A IL192507 A IL 192507A IL 19250708 A IL19250708 A IL 19250708A IL 192507 A0 IL192507 A0 IL 192507A0
Authority
IL
Israel
Prior art keywords
alpha
reducing agents
carbonyl compounds
hydroxy carbonyl
hydroxy
Prior art date
Application number
IL192507A
Other languages
English (en)
Original Assignee
Morvus Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morvus Technology Ltd filed Critical Morvus Technology Ltd
Publication of IL192507A0 publication Critical patent/IL192507A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/02—Treatment of flour or dough by adding materials thereto before or during baking by adding inorganic substances
    • A21D2/06—Reducing agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B31/00—Reduction in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Mechanical Engineering (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL192507A 2005-12-29 2008-06-29 Use of alpha-hydroxy carbonyl compounds as reducing agents IL192507A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0526552A GB0526552D0 (en) 2005-12-29 2005-12-29 New use
PCT/GB2006/004947 WO2007074344A1 (en) 2005-12-29 2006-12-29 Use of alpha-hydroxy carbonyl compounds as reducing agents

Publications (1)

Publication Number Publication Date
IL192507A0 true IL192507A0 (en) 2009-08-03

Family

ID=35841324

Family Applications (1)

Application Number Title Priority Date Filing Date
IL192507A IL192507A0 (en) 2005-12-29 2008-06-29 Use of alpha-hydroxy carbonyl compounds as reducing agents

Country Status (15)

Country Link
US (3) US9029569B2 (cg-RX-API-DMAC7.html)
EP (2) EP2258430B1 (cg-RX-API-DMAC7.html)
JP (2) JP5368803B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080091354A (cg-RX-API-DMAC7.html)
CN (4) CN107080746B (cg-RX-API-DMAC7.html)
AU (1) AU2006329678B2 (cg-RX-API-DMAC7.html)
CA (2) CA2826746C (cg-RX-API-DMAC7.html)
ES (2) ES2399288T3 (cg-RX-API-DMAC7.html)
GB (1) GB0526552D0 (cg-RX-API-DMAC7.html)
IL (1) IL192507A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008008616A (cg-RX-API-DMAC7.html)
NO (1) NO20082852L (cg-RX-API-DMAC7.html)
NZ (1) NZ569483A (cg-RX-API-DMAC7.html)
RU (2) RU2445078C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007074344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
EP2534957B1 (en) 2007-12-14 2015-05-27 AeroDesigns, Inc Delivering aerosolizable products
AU2009304542A1 (en) * 2008-10-15 2010-04-22 Xingnong Wang Use of tetrose to inhibit cancer and to increase cell viability
US20110216880A1 (en) * 2010-03-05 2011-09-08 General Electric Company System and method for molecular breast imaging
WO2011163671A2 (en) * 2010-06-25 2011-12-29 Boston Polymer Llc Environmentally benign plasticizers based on derivatives of acetone

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3208999A (en) 1964-09-09 1965-09-28 Nat Starch Chem Corp Preparation of non-inhibited starch amines
US3658788A (en) * 1969-06-06 1972-04-25 Salk Inst For Biological Studi Aminooxazolines and products thereof and processes for synthesizing same
US3711602A (en) * 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
JPS52145523A (en) 1976-05-28 1977-12-03 Kouki Yagishita Antiitumor agent
DE2730720C2 (de) 1977-07-07 1979-07-12 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von praktisch reinem l-Amino-8-nitro-43dihydroxy-anthrachinon
CA1089763A (en) 1978-10-30 1980-11-18 Willard J. Johnson Rodenticide comprising 6-aminonicotinamide and 6- aminonicotinohydroxamic acid
CS204501B1 (en) 1978-11-06 1981-04-30 Miroslav Dub Shaped trap for regulation of the numbers of exoantropous and hemisynantropous rodents classes
US4375394A (en) * 1982-03-11 1983-03-01 Eastman Kodak Company Electrolytic process for the preparation of ethylene glycol and glycerine
ATE66375T1 (de) * 1984-10-05 1991-09-15 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB8804068D0 (en) 1988-02-22 1988-03-23 Roberts J R Improvements relating to control of neoplastic tissue growth
CH680180B5 (cg-RX-API-DMAC7.html) * 1988-07-29 1993-01-15 Ciba Geigy Ag
DE3833194A1 (de) 1988-09-30 1990-04-05 Basf Ag Verfahren zum faerben von textilen materialien aus cellulosefasern
DE4103639A1 (de) * 1991-02-07 1992-08-13 Basf Ag Verfahren zum faerben von textilen materialien aus cellulosefasern
JP4115514B2 (ja) 1991-10-23 2008-07-09 キャンサー・リサーチ・キヤンペーン・テクノロジー・リミテツド Cb 1954およびその類似体を細胞障害性の形態に還元するための細菌のニトロリダクターゼ
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
DE4425436A1 (de) 1994-07-19 1996-01-25 Basf Ag Verfahren zur Herstellung von Acyloinen
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
US5632782A (en) 1994-09-01 1997-05-27 Clariant Finance (Bvi) Ltd. Exhaust dyeing process for sulphur dyes
US20040053208A1 (en) 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
WO1997023456A1 (en) 1995-12-21 1997-07-03 British Technology Group Ltd. Indoloquinone derivatives as bioreductive agents
NZ336381A (en) * 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
JP2001512425A (ja) 1997-02-11 2001-08-21 セラマーク・リミテッド 薬物ターゲティング
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB2365338B (en) 1997-06-14 2002-04-03 Enzacta R & D Ltd Therapeutic systems
US6159706A (en) 1997-12-23 2000-12-12 Newbiotics, Inc. Application of enzyme prodrugs as anti-infective agents
JP2002516304A (ja) 1998-05-22 2002-06-04 シオノギ・バイオリサーチ・コーポレーション 生体還元性細胞傷害剤
JP2002523382A (ja) 1998-08-19 2002-07-30 ザ・ビクトリア・ユニバーシテイ・オブ・マンチエスター 薬物ターゲティング
HK1049443A1 (zh) * 1999-11-12 2003-05-16 Angiotech Pharmaceuticals, Inc. 用放射活性疗法和细胞循环抑制剂联合治疗疾病的组合物和方法
AU783128B2 (en) 2000-03-02 2005-09-29 Innovata Plc TCF responsive element
CN1437594A (zh) * 2000-06-22 2003-08-20 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
DE10049468A1 (de) 2000-10-06 2002-04-11 Bayer Ag N-Alkoxyalkyl-substituierte Benzimidazole, ihre Herstellung und ihre Verwendung als Mittel gegen parasitäre Protozoen
DK1355566T3 (da) * 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
US20030228285A1 (en) 2002-05-03 2003-12-11 Mien-Chie Hung Bipartite T-cell factor (Tcf)-responsive promoter
GB0223696D0 (en) 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
GB0313604D0 (en) * 2003-06-12 2003-07-16 Britannia Pharmaceuticals Ltd Delivery device for powdered medicament
DE102004009434A1 (de) * 2004-02-24 2005-12-15 Boehringer Ingelheim International Gmbh Zerstäuber
FR2871697B1 (fr) 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
CA2570245A1 (en) 2004-07-02 2006-01-12 Warner-Lambert Company Llc Compositions and methods for treating pathological infections
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use

Also Published As

Publication number Publication date
CA2635388A1 (en) 2007-07-05
US20100104515A1 (en) 2010-04-29
AU2006329678A1 (en) 2007-07-05
ES2623857T3 (es) 2017-07-12
JP5368803B2 (ja) 2013-12-18
EP2258430A2 (en) 2010-12-08
JP2009522244A (ja) 2009-06-11
RU2011146556A (ru) 2013-05-27
MX2008008616A (es) 2008-11-27
CN101389320B (zh) 2016-02-03
US20180140575A1 (en) 2018-05-24
US10398676B2 (en) 2019-09-03
JP2013116904A (ja) 2013-06-13
JP5699170B2 (ja) 2015-04-08
EP1951213B1 (en) 2012-11-14
CN107080746B (zh) 2021-08-06
NZ569483A (en) 2012-09-28
WO2007074344A8 (en) 2007-12-27
CN101389320A (zh) 2009-03-18
US9029569B2 (en) 2015-05-12
CA2826746A1 (en) 2007-07-05
CN104188943B (zh) 2017-04-12
CA2826746C (en) 2016-08-16
KR20080091354A (ko) 2008-10-10
CA2635388C (en) 2016-08-16
RU2008131054A (ru) 2010-02-10
EP1951213A1 (en) 2008-08-06
AU2006329678B2 (en) 2013-05-09
ES2399288T3 (es) 2013-03-27
EP2258430A3 (en) 2011-06-08
WO2007074344A1 (en) 2007-07-05
CN107080746A (zh) 2017-08-22
CN104188943A (zh) 2014-12-10
RU2445078C2 (ru) 2012-03-20
NO20082852L (no) 2008-09-29
CN103315995B (zh) 2019-03-15
EP2258430B1 (en) 2017-03-22
CN103315995A (zh) 2013-09-25
US20150231113A1 (en) 2015-08-20
US9907784B2 (en) 2018-03-06
GB0526552D0 (en) 2006-02-08
HK1204269A1 (en) 2015-11-13

Similar Documents

Publication Publication Date Title
IL186616A0 (en) Spiro-oxindole compounds and their uses as therapeutic agents
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
PL2335782T3 (pl) Zastosowanie kompozycji zawierającej HFCO-1233zd
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
IL192395A0 (en) Modified lysine-mimetic compounds
IL189449A0 (en) Method for enhancing the effect of particulate benefit agents
PL2175273T3 (pl) Środek nadający kokumi
EP1864612A4 (en) ultrasonograph
IL190226A0 (en) Organometallic compounds and methods of use thereof
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
EP1880677A4 (en) ULTRASONOGRAPH
EP1824825A4 (en) PYRIDOXINES SUBSTITUTED AS ANTIPLATELET AGENTS
DK2392335T3 (en) Use of 24-norUDCA
IL186606A0 (en) Compositions and uses of amooranin compounds
EP1889660A4 (en) OZONE-GROWING AGENT
EP1927347A4 (en) MEANS TO REDUCE BITTERNESS
ZA200801208B (en) Anti-malarial composition
GB0511590D0 (en) Anti-thrombotic agents
HK1121071A (en) Use of alpha-hydroxy carbonyl compounds as reducing agents
GB0804899D0 (en) Compound composition and use
HK1106237A (en) New isothiazoloquinolones and related compounds as anti-infective agents
GB2422543B (en) Louse-killing agents
GB0510013D0 (en) Interaction of SNEV
GB0509642D0 (en) Therapeutics agents